20th week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110117023 | CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING AND PHOTOACOUSTIC IMAGING METHOD USING THE SAME - It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: | 2011-05-19 |
20110117024 | NANOCARRIER AND NANOGEL COMPOSITIONS - Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery. | 2011-05-19 |
20110117025 | DEVICE AND METHOD FOR FLUORESCENCE-BASED IMAGING AND MONITORING - A device for fluorescence-based imaging and monitoring of a target comprising: a light source emitting light for illuminating the target, the emitted light including at least one wavelength or wavelength band causing at least one biomarker associated with the target to fluoresce; and a light detector for detecting the fluorescence. | 2011-05-19 |
20110117026 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOACTIVE COMPOUNDS - The present invention provides compositions comprising delivery systems comprising a lipid vehicle, a bioactive compound, and a polyanionic carrier macromolecule that is not a carrier polynucleotide, wherein the lipid vehicle encapsulates the polynucleotide of interest and the polyanionic carrier macromolecule, and wherein the delivery system is essentially free of carrier polynucleotides. Compositions also include delivery systems comprising a lipid vehicle and a bioactive agent, wherein the lipid vehicle encapsulates the bioactive agent, and wherein the lipid vehicle comprises a covalent bilayer or a core supported bilayer comprising polycationic lipids. Other compositions provided herein comprise a delivery system comprising a polypeptide of interest and a means for delivering the polypeptide into a cell. Also provided herein are methods for making the delivery systems, methods for delivering bioactive compounds, methods for treating a disease or unwanted condition in a subject with the delivery systems, and methods for detecting apoptosis in a cell. | 2011-05-19 |
20110117027 | INJECTABLE VOID FILLER FOR SOFT TISSUE AUGMENTATION - The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition. | 2011-05-19 |
20110117028 | DEVICE AND METHOD FOR IN VIVO NONINVASIVE MAGNETIC MANIPULATION OF CIRCULATING OBJECTS IN BIOFLOWS - A device and methods for the non-invasive manipulation and detection of target objects such as cells, pathogens, microparticles, and nanoparticles in vivo using an external magnetic field are described. In one aspect, a device and method for capturing and detecting intrinsically magnetic target objects or target objects labeled with at least one magnetic particle within the area of interest using an in vivo flow cytometer are described. | 2011-05-19 |
20110117029 | WATER-SOLUBLE ANIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND THEIR USES - The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis. | 2011-05-19 |
20110117030 | Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections - A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler. | 2011-05-19 |
20110117031 | METHOD FOR TREATING HYPERSENSITIVE TEETH - A method for imparting a teeth-desensitising effect to a food, cosmetic or pharmaceutical which comprises combining said food, cosmetic or pharmaceutical with a teeth-desensitising effective amount of a polyol. | 2011-05-19 |
20110117032 | SANTISING COMPOSITIONS AND METHODS - Sanitising compositions are provided for use in combination with cleaning compositions, cleaning and sanitization protocols with such compositions and applications of such sanitising compositions. The compositions comprise (a) biocidal component comprising one or more non-polymeric biguanides and analogs thereof, and one or more quaternary ammonium compounds and a formulation comprising (b) one or more cationic detergents having at least one unsubstituted alkyl group of 8 or more carbon atoms, (c) one or more chelating agents, and (d) an amine component comprising a mixture of at least one alkanolamine and at least one bis(aminoalkyl)alkylamine. The composition may be further enhanced by the incorporation of a mixture of surfactants comprises as a first component one or more non-ionic surfactants and as a second component one or more amphoteric surfactants. The composition is particularly effective when used in combination with a cleaning composition comprising the same mixture of surfactants. | 2011-05-19 |
20110117033 | THERAPEUTIC AND PROPHYLACTIC FORMULATION FOR ORAL CARE - Technical result of invention lies in practical realization of high-efficient remineralizing formulation using available and cheap components. Due to absence of fluorides it can be recommended to patients suffering from fluorosis, endocrine system diseases for the purpose of caries prophylaxis and non-carious affections. The formulation contains acceptable active and inert components. To the group of active components there belongs complex including sources of elements of magnesium, sodium, silica and potassium in quantity 1-11 wt. %. Here are ratios of atomic masses of elements of magnesium, sodium, silica, potassium, parts of active components complex, correspondingly, 21.3:9.3:1.67:1. As a source of magnesium element there is used magnesium chloride or magnesium glycerophosphate or magnesium citrate. As a source of sodium element there is used sodium chloride or sodium silicate. As a source of silica element there is used sodium metasilicate or potassium metasilicate. As a source of potassium element there is used potassium silicate. | 2011-05-19 |
20110117034 | ULTRAVIOLET ABSORBER WATER-DISPERSED COMPOSITION - Disclosed is an ultraviolet absorber water-dispersed composition, comprising the following components (A) and (B);
| 2011-05-19 |
20110117035 | PROCESS FOR THE PREPARATION OF AQUEOUS SUSPENSIONS OF ANIONIC COLLOIDAL SILICA HAVING A NEUTRAL PH AND APPLICATIONS THEREOF - The instant invention relates to a process for the preparation of an aqueous suspension of anionic colloidal silica having a neutral pH which is stable over time and comprises individualized particles of colloidal silica which are not bound to one another by siloxane bonds. The instant suspensions show high storage stability and are particularly useful for the clarification of beer, for the preparation of cosmetic formulations, for the production of ink for printers, for paints and for anticorrosive treatments. | 2011-05-19 |
20110117036 | Compositions and Methods for Improving Skin Appearance - Skin conditioning compositions comprising a C4 to C30 monoalkyl-, dialkyl, monoalkanoyl- or dialkanoyl-substituted isohexide are found to exhibit a marked effect on skin hydration and barrier function homeostasis thereby improving skin appearances. | 2011-05-19 |
20110117037 | COMPOSITION COMPRISING AN ALKANOLAMINE, AN AMINO ACID AND AN ASSOCIATIVE POLYMER - The present invention provides a composition for treating keratin fibres, and especially human keratin fibres such as the hair, which comprises, in a cosmetically acceptable medium, one or more alkanolamines, one or more amino acids and one or more associative polymers. The present invention likewise provides methods of bleaching and/or colouring keratin fibres, and also multiple-compartment devices or kits for the implementation of these methods. | 2011-05-19 |
20110117038 | Dopa Oxidase Inhibitor, Skin-Lightening Agent and External Preparation for Skin - A dopa oxidase inhibitor, a skin-lightening agent and an external preparation for skin; comprising an extract of at least one plant selected from the group consisting of | 2011-05-19 |
20110117039 | ANTIOXIDANT, ANTI-INFLAMMATORY OR ANTI-AGING COMPOSITION CONTAINING TAXUS CAMBIUM- OR PROCAMBIUM-DERIVED CELL LINE AS ACTIVE INGREDIENT - The present invention relates to an antioxidant, anti-inflammatory or anti-aging composition containing any one or more of a | 2011-05-19 |
20110117040 | METHODS OF COATING EYELASHES AND EYELIDS WITH A LONG-WEARING MASCARA COMPOSITION - A method of coating eyelashes and/or eyelids with a cosmetic composition that includes from about 15% to about 50%, by weight, of a film former selected from the group consisting of tall oil glyceride, pentaerythrityl rosinate, glyceryl rosinate, and the hydrogenated versions and mixtures thereof. Further there is from about 0.1% to about 14%, by weight, of a colorant. In one embodiment of this invention the mascara composition comprises less than about 3.0%, preferably less than about 1.0%, even more preferably less than 0.1%, by weight, of wax and wax like components. In another embodiment, the mascara is substantially free of wax. The cosmetic composition is long lasting and has excellent wear characteristics. | 2011-05-19 |
20110117041 | COSMETIC COMPOSITION CONTAINING A SILICONE ACRYLATE AND A POLYESTER WAX. - A cosmetic composition for making up or caring for the skin includes, in a physiologically acceptable medium:
| 2011-05-19 |
20110117042 | POLYURETHANE DISPERSIONS FOR HAIR DYE - The present invention relates to a cosmetic composition for coloring a keratin-containing material, which includes one or more aqueous polyurethane dispersions | 2011-05-19 |
20110117043 | METHODS OF COATING EYELASHES AND EYELIDS WITH A LONG-WEARING MASCARA COMPOSITION - A method of coating eyelashes and/or eyelids with a cosmetic composition that includes from about 15% to about 50%, by weight, of a film former selected from the group consisting of tall oil glyceride, pentaerythrityl rosinate, glyceryl rosinate, and the hydrogenated versions and mixtures thereof. Further there is from about 0.1% to about 14%, by weight, of a colorant. The cosmetic composition is long lasting and has excellent wear characteristics. | 2011-05-19 |
20110117044 | Leave-In Hair Conditioning Composition - Present invention relates to a single-phase, transparent, non-aerosol and non-aqueous leave-in conditioning composition for hair, especially for strongly damaged hair by chemical processes such as permanent shaping, oxidative colouration and bleaching. Accordingly, conditioning compositions of present invention comprise one or more cyclomethicone at a concentration of at least 50% by weight calculated to total composition, and at least one di alkyl carbonate. | 2011-05-19 |
20110117045 | COMPOSITION FOR HAIR - It is an object of the present invention to provide a composition for hair which comprises highly safe nanoparticles having high transparency due to the small particle size and high permeability into hair and scalp. The present invention provides a composition for hair which comprises protein nanoparticles containing an active ingredient for hair. | 2011-05-19 |
20110117046 | NOVEL 4-ALKYL CYCLOHEXANEPROPANAL COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel 4-alkyl cyclohexanepropanal compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel compounds. | 2011-05-19 |
20110117047 | CYANOACRYLATE TISSUE ADHESIVES WITH DESIRABLE PERMEABILITY AND TENSILE STRENGTH - A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m | 2011-05-19 |
20110117048 | METHOD AND COMPOSITION FOR USE IN PREPARATION OF A PATIENT FOR SURGERY - Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc.) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal “resident” micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both “transient” and “resident” micro-organisms. | 2011-05-19 |
20110117049 | Methods and Compositions for Modulating Adipocyte Function - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. | 2011-05-19 |
20110117050 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen - The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration. | 2011-05-19 |
20110117051 | METHOD FOR INDUCING AND ACCELERATING CELLS - The present invention relates to a method for the production of functional dendritic cells wherein CD34 positive cells are contacted with compounds inducing and accelerating the differentiation of these CD34 positive cells into functional dendritic cells. More in particular, the CD34 positive cells are contacted with anthracyclines and/or anthracenediones. In another aspect, the current invention relates to the cells obtainable by the method according to the invention. In a further aspect the current invention relates to the use of compounds such as anthracyclines and/or anthracenediones that induce and accelerate the differentiation of CD34 positive cells into functional dendritic cells in the manufacture of a medicament for inducing an immune response in human in need thereof. | 2011-05-19 |
20110117052 | METHODS OF TREATMENT USING IL-31RA - The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist. | 2011-05-19 |
20110117053 | METHOD OF MODULATING FIBROBLAST ACCUMULATION OR COLLAGEN DEPOSITION - The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine. | 2011-05-19 |
20110117054 | USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER - To provide a pharmaceutical agent that is effective for the amelioration or the like of a condition where the prothrombin time is prolonged or a condition where the INR (international normalized ratio) is increased. Disclosed is a pharmaceutical agent comprising ribavirin or a derivative thereof as an active ingredient. | 2011-05-19 |
20110117055 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds - Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus infection in a subject in need thereof. | 2011-05-19 |
20110117056 | DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV. | 2011-05-19 |
20110117057 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. | 2011-05-19 |
20110117058 | METHOD OF TREATING GENETIC DISORDERS - A method for the treatment of diseases associated with mutations in MYO7A or CEP290 genes, especially the Usher Syndrome type IB and Leber congenital amaurosis, by administering to a subject in need thereof an adeno-associated viral vector encoding a MYO7A or a CEP290 protein; genetic constructs and adeno-associated viral vectors for use in this method. | 2011-05-19 |
20110117059 | COMPOSITION OF SOLUBLE INDIGESTIBLE FIBRE AND OF MICROALGAE USED IN THE WELL-BEING FIELD - Described is the use of soluble indigestible fibre for inducing lysis of the cell walls of eukaryotic microalgae in the lumen of the intestine of an omnivorous or carnivorous animal including an intestinal flora and also for synergistically increasing the effect of the indigestible fibre in the induction of the growth of the intestinal flora of an omnivorous or carnivorous animal. The subject matter of the invention is also the composition intended for this use and for a method of improving the health or of food supplementation. | 2011-05-19 |
20110117060 | CANCER TREATMENT USING VIRUSES, FLUOROPYRIMIDINES AND CAMPTOTHECINS - Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. | 2011-05-19 |
20110117061 | Ex Vivo Expansion of Human Hematopoietic Stem Cells - Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated IGFBP-2 and an angiopoietin-like protein (Angptl). Expanded HSCs are provided as well as culture media and kits for the expansion of human HSCs in a defined medium. Methods of administering expanded human HSCs to and individual are provided as well as methods of treating an individual by administering certain growth factors and cytokines. | 2011-05-19 |
20110117062 | Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2011-05-19 |
20110117063 | Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells For Treatment of Retinal Degeneration - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2011-05-19 |
20110117064 | ASSAY FOR THE PREDICTION OF THERAPEUTIC EFFECTIVENESS OF MESENCHYMAL STROMAL CELLS, AND METHODS OF USING SAME - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations. | 2011-05-19 |
20110117065 | COMPOSITIONS AND METHODS FOR USING CELLS TO TREAT HEART TISSUE - This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue. | 2011-05-19 |
20110117066 | ESTABLISHED HUMAN BROWN ADIPOCYTE LINE AND METHOD FOR DIFFERENTIATION FROM AN HMADS CELL LINE - The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bcl2 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual. | 2011-05-19 |
20110117067 | Glucanases, Nucleic Acids Encoding Them and Methods for Making and Using Them - The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability, including thermotolerance or thermostability, at increased or decreased pHs and temperatures. | 2011-05-19 |
20110117068 | PROBIOTIC MICROORGANISMS FOR THE REDUCTION OF MANURE ODOR - Described are microorganism which are able to reduce the generation of feces odor by decreasing the amount of at least one of the compounds methyl mercaptan, a sulphide compound, cadavarine, putrescine, indole or skatole, and wherein said decrease in the amount of said compounds is independent of the growth of the microorganism. Also described are compositions, comprising such microorganisms, e.g. food, feed or pharmaceutical compositions and the use of such microorganisms for suppressing feces odor or the preparation of foodstuff or feedstuff, as well as corresponding methods for the production of food or feed composition and additives for food, feed or drinks. | 2011-05-19 |
20110117069 | METHOD FOR ACTIVATING REGULATORY T-CELLS - The invention relates to a method for activating regulatory t-cells (Treg-cells) of the human or animal body, comprising a step of bringing into contact the regulatory t-cells (Treg-cells) in a suitable liquid medium with one or a plurality of inhibitors of alanyl-amino peptidase (amino peptidase N; APN) and/or with one or a plurality of inhibitors of peptidases with the same substrate specificity to induce a suppressive effect of the regulatory t-cells (Treg-cells). | 2011-05-19 |
20110117070 | COMPOSITIONS AND METHODS FOR TREATING HEADACHE - Compositions and methods for the treatment of headaches, such as migraine and cluster headaches, comprising co-administration of a first therapeutic component comprising topiramate and a second therapeutic component comprising a therapeutically effective amount or mixture of one or more therapeutic agents selected from the group consisting of riboflavin, magnesium, coenzyme Q10, petasin, isopetasin, and parthenolide. Also disclosed are methods for increasing the efficacy, and reducing or preventing side effects, of topiramate treatment. | 2011-05-19 |
20110117071 | Antimicrobial Composition - The present invention relates to an improved antimicrobial composition comprising a hydrogen peroxide source and one or more antimicrobial agents. Ideally, the invention relates to an antimicrobial composition comprising (i) hydrogen peroxide source and (ii) an antimicrobial agent and its associated use in therapy, particularly in the treatment of antimicrobial infections. | 2011-05-19 |
20110117072 | HYPERACTIVE VARIANTS OF THE TRANSPOSASE PROTEIN OF THE TRANSPOSON SYSTEM SLEEPING BEAUTY - The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed. | 2011-05-19 |
20110117073 | Protein Kinase Conjugates and Inhibitors - The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases. | 2011-05-19 |
20110117074 | METHODS OF TREATING HIV AND INFLUENZA INFECTIONS USING ASPERGILLUS ORYZAE PROTEASE - The invention provides methods for treating viral diseases such as HIV infection and influenza infection in a subject in need of treatment, comprising orally administering to the subject a composition comprising a therapeutically effective amount of an | 2011-05-19 |
20110117075 | THROMBIN DERIVED PEPTIDES FOR SMOOTH MUSCLE RELAXATION - Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be administered to a subject with a disease or disorder that can be ameliorated by relaxation of smooth muscle. Such compositions can also be administered to a subject to facilitate medical, diagnostic or surgical procedures. | 2011-05-19 |
20110117076 | Method for Preparing Raw Material for Functional Foods from Barley or Wheat Seeds - A method is provided for preparing a raw material for functional foods from vernalized, pre-germinated barley or wheat seeds, plumules cultured the vernalized, pre-germinated barley or wheat seeds, or a material resulting from the fermentation of the vernalized, pre-germinated barley or wheat seeds with lactic acid bacteria. | 2011-05-19 |
20110117077 | NUTRITIONAL COMPOSITION FOR INFANTS DELIVERED VIA CAESAREAN SECTION - The present invention relates to methods for feeding of infants delivered via caesarean section and to compositions to be administered to infants delivered via caesarean section and in particular to the use of a product obtained by fermentation of milk, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate and/or lactose by lactic acid producing bacteria. Thereby it is possible to stimulate a fast colonisation of the intestinal microbiota of said infants. | 2011-05-19 |
20110117078 | Methods for the Treatment of Cancers - Methods for the treatment of cancers involving dysregulation of thromboxane receptor β (TP-β) are provided, including in certain aspects methods for diagnosing such cancers. Specific cancers included are genitourinary cancers, gastrointestinal cancers and leukemias. | 2011-05-19 |
20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 2011-05-19 |
20110117080 | Anti-REG4 Antibodies - Antibodies to human REG4 are provided, as well as uses thereof, e.g., in treatment of proliferative disorders. Also provided is a method of screening for an antibody that inhibits REG4 bioactivity. | 2011-05-19 |
20110117081 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS - A compound of Formula (1) or a salt thereof, methods for the preparation and use of such a compound, especially as an IAP inhibitor, and related compounds, compositions, and methods. | 2011-05-19 |
20110117082 | Soluble Tumor Necrosis Factor Receptor Mutant - A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases. | 2011-05-19 |
20110117083 | BIOLOGICAL MARKERS FOR MONITORING PATIENT RESPONSE TO VEGF ANTAGONISTS - The invention provides methods and compositions to detect expression of one or more biomarkers for monitoring the effectiveness of treatment of with VEGF antagonists. The invention also provides methods for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2011-05-19 |
20110117084 | VANDETANIB DERIVATIVES - This invention relates to novel quinazoline derivatives and their acceptable acid addition salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibitory activity against the VEGF receptor tyrosine kinase. | 2011-05-19 |
20110117085 | MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT - The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent. | 2011-05-19 |
20110117086 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES - The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer. | 2011-05-19 |
20110117087 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN - Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture. | 2011-05-19 |
20110117088 | COMPOSITION AND METHOD FOR INTRODUCTION OF RNA INTERFERENCE SEQUENCES INTO TARGETED CELLS AND TISSUES - A composition and method are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues. Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by internalization of a target cell specific ligand to which the double-stranded RNA containing a small interfering RNA nucleotide sequence is conjugated. The ligand is specific to a unique target cell surface antigen. The ligand is either spontaneously internalized after binding to the cell surface antigen. Internalization is also facilitated by the binding of an RNA binding protein to the double-stranded RNA. If the unique cell surface antigen is not naturally internalized after binding to its ligand, internalization is promoted by the incorporation of a peptide into the structure of the ligand or attachment of such a peptide to the ligand. | 2011-05-19 |
20110117089 | BCR-Complex-Specific Antibodies And Methods Of Using Same - This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 2011-05-19 |
20110117090 | ADAM-15 ANTIBODIES AND IMMUNOGENIC PEPTIDES - The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules. | 2011-05-19 |
20110117091 | HUMANIZATION OF RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK - The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 2011-05-19 |
20110117092 | COMPOSITIONS AND METHODS FOR INHIBITING G-CSFR - The present invention relates to therapeutic targets for multiple sclerosis and other inflammatory and neurological diseases. In particular, the present invention relates to altering G-CSF/G-CSFR signaling in the treatment of such disorders. | 2011-05-19 |
20110117093 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 2011-05-19 |
20110117094 | Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury - Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent. | 2011-05-19 |
20110117095 | GROWTH FACTOR HTTER36 - The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include the diagnosis, prevention, and treatment of wasting disorders. Also disclosed are antagonists against such polypeptide and their therapeutic uses which include the diagnosis, prevention, and treatment of obesity and obesity-related disorders. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention. | 2011-05-19 |
20110117096 | Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 Antibodies - Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4. | 2011-05-19 |
20110117097 | HER2 ANTIBODY COMPOSITION - A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed. | 2011-05-19 |
20110117098 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 2011-05-19 |
20110117099 | INHIBITING STAPHYLOCOCCUS EPIDERMIDIS INFECTIONS - The invention relates to | 2011-05-19 |
20110117100 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, STRATIFICATION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Natural human autoantibodies against toxic assemblies of Aβ and related peptide species offer a unique immune repertoire. Based on this repertoire, the present invention provides compositions and methods for diagnosis as well as for prophylactic and therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease that are characterized by accumulation of beta-amyloid deposits. The same human autoantibodies may be useful for prophylactic and therapeutic treatment of other neurodegenerative disorders and systemic pathological conditions that are due to or are associated with toxic assemblies of other amyloidogenic peptides or proteins. | 2011-05-19 |
20110117101 | CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION - The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV. | 2011-05-19 |
20110117102 | Therapeutic uses of inhibitors of RTP801 - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein. | 2011-05-19 |
20110117103 | ANTI-SWEAT ANTIGEN MONOCLONAL ANTIBODY - [Object of the Invention] To provide an antibody that inhibits histamine releasing activity induced by an antigenic substance contained in sweat. | 2011-05-19 |
20110117104 | MONOCLONAL ANTIBODY SPECIFIC TO ANTHRAX TOXIN - Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin. | 2011-05-19 |
20110117105 | METHOD OF TREATING IMMUNE DISEASE USING B-CELL ANTIBODIES - Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent. | 2011-05-19 |
20110117106 | USES OF CALPAIN INHIBITORS TO INHIBIT INFLAMMATION - Calpains target junctional components that normally seal the epithelium, forming tight junctions. This selective targeting by calpains facilitates the transmigration of leukocytes across the epithelium and into tissue spaces where they can cause inflammation. The present disclosure provides methods of using calpain inhibitors to prevent epithelial junction reorganization such that leukocyte transmigration is inhibited and accordingly, inflammation reduced or prevented. These methods can at least be used to reduce respiratory inflammation by preventing leukocyte accumulation in pulmonary airways. | 2011-05-19 |
20110117107 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND MANAGEMENT OF MALARIA - Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1β, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control. | 2011-05-19 |
20110117108 | TREATMENT AND PREVENTION OF CANCEROUS AND PRE-CANCEROUS CONDITIONS OF THE LIVER, LUNG AND ESOPHAGUS - The invention relates to the treatment and/or prevention of cancerous and/or, precancerous conditions of the liver, lung and esophagus by actively and/or passively immunizing a patient against the peptide hormone gastrin and/or a gastrin receptor, e.g., the CCK-B/gastrin receptor. The immunizations of the invention may be employed as a monotherapy, an adjunctive therapy, or as part of a combination therapy. | 2011-05-19 |
20110117109 | CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES - The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell. | 2011-05-19 |
20110117110 | ANTI-EGFR ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR. | 2011-05-19 |
20110117111 | MICRORNA-BASED DIAGNOSTIC TESTING AND THERAPIES FOR INFLAMMATORY BOWEL DISEASE AND RELATED DISEASES - The present invention is based, at least in part, on the novel discovery that certain microRNAs are associated with inflammatory bowel diseases and other related diseases. Accordingly, the invention relates to microRNA-based compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating inflammatory bowel diseases and other related diseases. | 2011-05-19 |
20110117112 | SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same. | 2011-05-19 |
20110117113 | IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN DIRECTED AGAINST HUMAN CXCR4 AND OTHER CELL ASSOCIATED PROTEINS AND METHODS TO GENERATE THEM - The invention relates to immunoglobulin single variable domains directed against specific human CXCR4 epitopes (herein also referred to interchangeably as “compounds of the invention”, “amino acid sequences of the invention”, or “building blocks of the invention”) and polypeptides comprising them (herein also referred to as “polypeptides of the invention”, “compounds of the invention”, or “constructs of the invention”). | 2011-05-19 |
20110117114 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 2011-05-19 |
20110117115 | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders - Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide, and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions. | 2011-05-19 |
20110117116 | NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, DER P III, AND USES THEREFOR - Isolated nucleic acids encoding an allergen of | 2011-05-19 |
20110117117 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2011-05-19 |
20110117118 | MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUSES - A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions. | 2011-05-19 |
20110117119 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c protein sequence for use in the treatment or prevention of latent TB. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of latent tuberculosis. | 2011-05-19 |
20110117120 | Plasmodium falciparum HLA class I restricted T-cell epitopes - The invention relates immunogenic polypeptides and epitopes from | 2011-05-19 |
20110117121 | COMPOSITIONS FOR TREATMENT AND INHIBITION OF PAIN - Methods and compositions for therapy of pain are provided. Compositions comprising therapeutically effective amounts of two or more of an extract of | 2011-05-19 |
20110117122 | COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB - The present invention discloses a composition and method for effecting various cytokines and NF-κB by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including HIV by regulation of various interleukins, such as IL-10 and IL-2, and of transcription factors including NF-κB. | 2011-05-19 |